Health Care · Services-Medical Laboratories

LH Labcorp SEC Filings & Insider Trading Activity 2026

company
CIK 920148153 filings
S&P 500

LH at a glance

Labcorp (LH, SEC CIK 920148) filed its latest 10-K annual report on February 24, 2026, a 10-Q quarterly report on October 30, 2026, an 8-K current report on November 4, 2026 and Form 4 insider filings as recently as November 18, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), Labcorp (LH) reported revenue of $14.0 billion (up 7.2% from FY2024) and net income of $876.5 million. Diluted EPS was $10.46.
  • As of September 30, 2026, 41 institutional investment managers tracked by SignalX reported holding Labcorp (LH) shares worth $9.3 billion in 13F-HR filings.
  • The most recent insider open-market sale reported on Form 4 was by Summy Amy B. on November 16, 2026 of 365 shares at $372.58 per share.
  • In the last 90 days, LH insiders reported 0 open-market purchases ($0) and 4 open-market sales ($1.4M) on Form 4, a net sale of $1.4M.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$14.0B
+7.2% vs prior year
Insiders · 90 days
0 buys · 4 sells
Net −$1.4M
13F holders
41 funds
$9.3B · −2 vs prior quarter
Latest 8-K
Nov 4, 2026
Item 7.01

AI 10-K Annual Report Analysis

Latest 10-K, fiscal year ended Dec 31, 2025

Full analysis →

Management Discussion & Analysis

  • Revenue $13,951.7 in FY2025, up 7.2% YoY from $13,008.9; driven by 4.4% organic growth, 2.5% acquisitions net of divestitures, 0.4% FX tailwind
  • Operating margin 9.9% vs 8.4% YoY; cost of revenues fell to 71.2% vs 72.1%; SG&A fell to 15.9% vs 17.1% of revenue
  • Best segment: Dx operating income $1,779.9 (+10.8% YoY), margin 16.4% vs 15.8%; BLS operating income $498.5 (+8.6%), margin 16.1% vs 15.7%
  • Operating cash flow $1,640.5 vs $1,585.8; capex $434.5 (3.1% of revenue); dividends $240.7; share repurchase authorization remaining $830.4
  • OBBBA legislation risk flagged: potential Medicaid/ACA coverage reduction; capex guided higher to ~4.0% of revenue in 2026; pending acquisitions (Empire City, Parkview) up to $415.0

Risk Factors

  • Ravgen patent verdict: $272M jury award + $100M enhanced damages + $2.6M supplemental + $100/test ongoing royalty through patent life
  • PAMA Medicare reimbursement cuts frozen 2026, resuming 2027–2029 capped at 15%/year with further reductions possible thereafter
  • Senior notes $5.2B outstanding, $500M due within 12 months, plus $1.0B revolving credit facility with leverage ratio covenants
  • FDA's April 2024 LDT final rule rescinded after legal challenge, but potential reissuance could impose device-level regulatory burden on core lab testing
  • BLS dependent on specialized research animal supply; import restrictions or activist disruption could halt preclinical services with no short-term substitute

Business Overview

  • Dual-segment lab services platform: Dx (clinical testing, $10.9B revenue) and BLS (drug development services, $3.1B revenue), total revenues $13.95B
  • New specialty test launches in 2025: Alzheimer's disease diagnostics, molecular residual disease detection, expanded oncology precision testing; also nationwide self-collection HPV/STI testing via Labcorp OnDemand
  • Strategic pivot toward health system partnerships (13 signed/completed in 2025) and international expansion via minority stake acquisition in SYNLAB, Europe's diagnostic services leader
  • BLS supported 85% of FDA-approved drugs/therapeutic products in 2025; $582M deployed in acquisitions; $450M in share buybacks at avg $254.17/share
  • Launched more than 130 new Dx tests in 2025 while expanding cell and gene therapy lab capacity in Madison, WI: targeting ~2,000 active global CGT clinical trials representing ~20% of biopharma pipelines

AI summary of the LH 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Risk Factors

  • New ERP implementation risk, triggered by planned deployment across broader Company areas
  • ERP integration and data migration failures, potentially disrupting supply chain, procurement, and transaction processing
  • Third-party provider failures, including cybersecurity incidents, potentially exposing confidential information and creating regulatory obligations
  • ERP-related inventory purchases, potentially pressuring cash flows and liquidity

Management Discussion & Analysis

  • Revenue $3,810.0M, up 6.9% YoY from $3,563.5M, driven by 5.5% organic growth
  • Operating income $402.1M, up 1.4% YoY from $396.6M
  • BLS strongest segment: revenue $866.7M, up 8.5%; margin 18.3% vs 16.5%
  • Operating cash flow $1,200.8M vs $1,026.3M; cash $261.8M at September 30, 2026
  • Capital expenditures $404.2M; management cites higher interest costs and potential refinancing pressure as headwinds

AI summary of the LH 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 4, 2026Full analysis →

Item 7.01: Regulation FD Disclosure

  • CFO Julia Wang scheduled to speak at UBS Global Healthcare Conference on November 10, 2026
  • Investor webcast at 8:45 a.m. ET, with replay available for 180 days

Item EX-99.1: Item EX-99.1

  • CFO Julia Wang scheduled to speak November 10 at the UBS Global Healthcare Conference
  • Fireside chat webcast may provide updates on strategy, operating trends and capital allocation
Filed Oct 28, 2026Full analysis →

Item EX-99.1: Item EX-99.1

  • Q3 revenue $3.81B, up 6.9%, with adjusted EPS $4.78, up 14.5%, signaling continued operating leverage
  • Adjusted operating margin expanded to 15.0% from 14.4%, driven by organic growth and operating efficiencies
Filed Oct 21, 2026Full analysis →

Item 7.01: Regulation FD Disclosure

  • Quarterly cash dividend declared at $0.72 per common share
  • Payment scheduled for December 11, 2026

Item EX-99.1: Item EX-99.1

  • Quarterly cash dividend declared at $0.72 per common share
  • Record date November 24, 2026, determining shareholder eligibility

AI summaries of LH 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for LH

Don't miss the next LH filing

  • Alerts as it files. A push when LH files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut LH, by share count.
  • Ask anything. An AI agent that reads every LH filing and answers with sources.

LH alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Summy Amy B.SellNov 16, 2026$372.58
Caveney Brian JSellNov 10, 2026$372.04
Vaughn Bryan TSellNov 3, 2026$353.70
Oyegunwa AkinboladeFNov 2, 2026$355.59
Vaughn Bryan TFNov 2, 2026$355.59
Oyegunwa AkinboladeMNov 1, 2026-
Vaughn Bryan TMNov 1, 2026-
Vaughn Bryan TMNov 1, 2026-

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue-$13.0B$14.0B
Gross Profit-$3.6B$4.0B
Operating Income-$1.1B$1.4B
Net Income-$746.0M$876.5M
Gross Margin-27.9%28.8%
Op. Margin-8.4%9.9%
Net Margin-5.7%6.3%
Balance Sheet
Total Assets$16.7B$18.4B$18.4B
Equity-$8.1B$8.6B
ROE-9.3%10.2%
Per Share
EPS-$8.84$10.46
Cash Flow
Operating CF-$1.6B$1.6B
CapEx$453.6M$489.9M$434.5M

Source: XBRL data in Labcorp (LH)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate LH share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
LH shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202641$9.25B
Q2 202643$8.74B
Q1 202639$8.17B
Q4 202536$7.98B
Q3 202538$10.18B
Q2 202535$9.38B
Q1 202535$6.14B
Q4 202433$5.47B
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions
None this quarter.
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 300 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

LH filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
4Nov 18, 2026--
4Nov 12, 2026--
4Nov 5, 2026--
8-KNov 4, 2026Analysis-
4Nov 3, 2026--
4Nov 3, 2026--
4Nov 3, 2026--
10-QOct 30, 2026Analysis
8-KOct 28, 2026Analysis-
8-KOct 21, 2026Analysis-
8-KSep 30, 2026Analysis-
8-KSep 22, 2026Analysis-
8-KSep 10, 2026Analysis-
4Sep 3, 2026--
4Sep 3, 2026--
4Sep 3, 2026--
4Sep 3, 2026--
8-KAug 28, 2026Analysis-
4Aug 18, 2026--
8-KAug 17, 2026Analysis-
8-KAug 14, 2026Analysis-
4Aug 12, 2026--
4Aug 6, 2026--
10-QAug 5, 2026Analysis
4Aug 5, 2026--

Related Health Care companies

All Health Care →

LH SEC filings: frequently asked questions

Are LH insiders buying or selling?

In the last 90 days, Labcorp (LH) officers, directors and 10% owners reported no open-market purchases and 4 open-market sales worth $1.4 million by 4 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold LH stock?

As of September 30, 2026, the largest Labcorp (LH) holders among the 13F filers tracked by SignalX were BlackRock ($2.0 billion), Vanguard Capital Management LLC ($1.6 billion), State Street Corp ($1.2 billion), Vanguard Portfolio Management LLC ($1.1 billion), Morgan Stanley ($491.7 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was LH's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), Labcorp (LH) reported revenue of $14.0 billion (up 7.2% from FY2024) and net income of $876.5 million. Diluted EPS was $10.46. The figures come from the XBRL data in the 10-K.

What are the main risks in LH's latest 10-K?

In the 10-K filed February 24, 2026, Labcorp (LH) flagged: Ravgen patent verdict: $272M jury award + $100M enhanced damages + $2.6M supplemental + $100/test ongoing royalty through patent life. PAMA Medicare reimbursement cuts frozen 2026, resuming 2027–2029 capped at 15%/year with further reductions possible thereafter. (AI summary of the Risk Factors section.)

What did LH report in its latest 8-K?

Labcorp (LH) filed an 8-K on November 4, 2026 reporting Item 7.01 (Regulation FD Disclosure). CFO Julia Wang scheduled to speak at UBS Global Healthcare Conference on November 10, 2026.

What are the latest LH SEC filings?

Labcorp (LH) filed its latest 10-K annual report on February 24, 2026, a 10-Q quarterly report on October 30, 2026, an 8-K current report on November 4, 2026 and a Form 4 insider filing on November 18, 2026.

What is LH's SEC CIK number?

Labcorp (LH)'s SEC Central Index Key (CIK) is 920148. EDGAR lists every LH filing under that number.

Ask anything about LH

The research agent reads LH's filings, financials, insider trades and 13F holders, then answers with sources.